Short Interest in Catalent, Inc. (NYSE:CTLT) Grows By 7.3%

Catalent, Inc. (NYSE:CTLT - Get Free Report) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 9,060,000 shares, a growth of 7.3% from the October 31st total of 8,440,000 shares. Based on an average trading volume of 1,760,000 shares, the short-interest ratio is currently 5.1 days.

Catalent Trading Up 0.5 %

Shares of CTLT stock traded up $0.29 during trading hours on Tuesday, hitting $61.72. 4,220,956 shares of the company were exchanged, compared to its average volume of 1,828,331. Catalent has a one year low of $36.74 and a one year high of $62.08. The business's 50-day simple moving average is $59.93 and its two-hundred day simple moving average is $58.55. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period last year, the company posted ($0.10) earnings per share. On average, equities research analysts forecast that Catalent will post 0.84 EPS for the current year.

Insider Transactions at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the company's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares of the company's stock, valued at $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,114 shares of company stock valued at $305,931. Corporate insiders own 0.31% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Oddo BHF Asset Management Sas acquired a new position in Catalent during the 3rd quarter valued at about $8,480,000. Tidal Investments LLC acquired a new position in shares of Catalent during the third quarter valued at approximately $214,000. Neo Ivy Capital Management acquired a new position in shares of Catalent during the third quarter valued at approximately $1,078,000. Nomura Asset Management Co. Ltd. raised its holdings in Catalent by 1.4% during the third quarter. Nomura Asset Management Co. Ltd. now owns 53,011 shares of the company's stock worth $3,211,000 after purchasing an additional 750 shares in the last quarter. Finally, National Bank of Canada FI lifted its position in Catalent by 300.0% in the third quarter. National Bank of Canada FI now owns 1,460,813 shares of the company's stock worth $88,481,000 after purchasing an additional 1,095,578 shares during the period.

Analysts Set New Price Targets

CTLT has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Catalent from a "sell" rating to a "hold" rating in a report on Monday. Baird R W lowered shares of Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. William Blair reiterated a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Robert W. Baird restated a "neutral" rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. Eight equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, Catalent currently has a consensus rating of "Hold" and a consensus price target of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.